Syn2bio (WAR:S2B) Total Equity: zł16.68 Mil (As of Sep. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

WAR:S2B Syn2bio SA WAR:S2B
11 GF Score
Price zł81.40
! 2 Warning Signs
View Full Analysis

What is Syn2bio Total Equity?

Syn2bio WAR:S2B +1.88% 11 Total Equity is zł16.68 Mil as of Sep. 2025. GuruFocus rates WAR:S2B with a GF Score™ of 11/100. The stock has 2 warning signs investors should review.

Syn2bio's total equity for the quarter that ended in Sep. 2025 was zł16.68 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Syn2bio Total Equity Historical Data

* Premium members only.

The historical data trend for Syn2bio's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Syn2bio Total Equity Chart

Syn2bio Annual Data
Trend Sep23 Sep24 Sep25
Total Equity
11.43 18.85 16.68

Syn2bio Semi-Annual Data
Sep23 Sep24 Sep25
Total Equity 11.43 18.85 16.68
WAR:S2B
11GF Score
Syn2bio SA WAR:S2B
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Syn2bio Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Syn2bio's Total Equity for the fiscal year that ended in Sep. 2025 is calculated as

Total Equity=Total Assets(Q: Sep. 2025 )-Total Liabilities(Q: Sep. 2025 )
=26.206-9.53
=16.68

Syn2bio's Total Equity for the quarter that ended in Sep. 2025 is calculated as

Total Equity=Total Assets(Q: Sep. 2025 )-Total Liabilities(Q: Sep. 2025 )
=26.206-9.53
=16.68

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of zł16.68 Mil mean?
Syn2bio (WAR:S2B) has a Total Equity of zł16.68 Mil as of Sep. 2025. The total amount of equity as record on a company's balance sheet. View historical data for Syn2bio and its competitors.
Is Syn2bio's Total Equity too high?
Syn2bio's current Total Equity is zł16.68 Mil. Overall, Syn2bio has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Syn2bio's Total Equity compare to VRTX and REGN?
Syn2bio's Total Equity of zł16.68 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Biotechnology company?
A good Total Equity depends on the Biotechnology industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Syn2bio and its competitors. Syn2bio's current Total Equity is zł16.68 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Syn2bio stock overvalued right now?
Syn2bio (WAR:S2B) has a current Total Equity of zł16.68 Mil. The current Total Equity is zł16.68 Mil. Syn2bio's overall GF Score™ is 11/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Syn2bio (WAR:S2B), the current Total Equity is zł16.68 Mil as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Syn2bio Business Description

Address ul. Jozefa Piusa Dziekonskiego 3, Warszawa, POL, 00-728
Syn2bio SA is a Polish biotech company that develops radiopharmaceuticals. It specializes in developing a cardiac biomarker for diagnosing heart conditions like coronary artery disease through myocardial perfusion imaging. The company's flagship product is the SYN2 cardiotracer. It is applied in the detection of perfusion disorders, evaluation of patients after myocardial infarction or with ischemic heart disease, and assessment of atherosclerotic changes in coronary arteries.
11GF Score

Get the complete analysis for WAR:S2B

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

zł81.40
Price